References in periodicals archive ?
Piper Jaffray analyst Edward Tenthoff raised his price target for Vericel (VCEL) to $16 from $14 after Histogenics (HSGX) reported its Phase III trial of NeoCart to repair knee cartilage defects narrowly missed its primary endpoint of dual threshold responder analysis compared to microfracture in 249 patients at one-year.
CAMBRIDGE, Mass., May 10, 2017 -- The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) status for ixmyelocel-T, a product of Vericel Corporation (VCEL), developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions.
The company's common stock will begin trading on 25 November 2014 with the opening of market on the NASDAQ Capital Market under its new stock ticker symbol 'VCEL'.
Vericel (VCEL), up 9% after reporting quarterly results...
Carticel from Sanofi's (SNY) Genzyme unit and MACI from Vericel (VCEL) have received FDA approval for the culturing of chondrocytes through a biologics license for specific indications.
Acronyms browser ?
Full browser ?
- VCE smear
- vCenter Mobile Access
- VCenter Server Appliance
- VCF syndrome